Gefitinib NEW

Description:

Gefitinib is a medication used in the treatment of non-small cell lung cancer (NSCLC) that has specific mutations in the epidermal growth factor receptor (EGFR) gene. 

It belongs to a class of drugs known as tyrosine kinase inhibitors, which work by blocking the activity of the EGFR protein, a key driver of cancer cell growth and proliferation.

Gefitinib is taken orally in the form of a tablet. It is typically prescribed for patients with advanced or metastatic NSCLC whose cancer has specific EGFR mutations. 

Gefitinib helps to slow down the growth and spread of cancer cells, shrink tumors, and improve symptoms in patients with this type of lung cancer.

Common side effects of gefitinib may include diarrhea, skin rash, nausea, loss of appetite, and fatigue. 

These side effects are usually manageable and can be addressed with supportive care. It is important to report any severe or persistent side effects to a healthcare provider.

Gefitinib is an important medication in the treatment of NSCLC and has shown efficacy in patients with specific EGFR mutations. 

It is essential to work closely with a healthcare provider to determine if gefitinib is the right treatment option and to monitor for any potential side effects or complications associated with its use.

Payment method: T/T in advance, Paypal, Western Union, L/C, etc.

Shipping ways: Courier, Air, Sea, Road

Storage Condition: Dry, dark, and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).